SenzaGen AB (SENZA.ST)

SEK 5.26

(-0.38%)

EBITDA Summary of SenzaGen AB

SenzaGen AB's latest annual EBITDA in 2023 was -13.53 Million SEK , up 38.02% from previous year.
SenzaGen AB's latest quarterly EBITDA in 2024 Q1 was 1.92 Million SEK , up 108.79% from previous quarter.
SenzaGen AB reported an annual EBITDA of -15.35 Million SEK in 2022, up 60.95% from previous year.
SenzaGen AB reported an annual EBITDA of -27.07 Million SEK in 2021, down -16.74% from previous year.
SenzaGen AB reported a quarterly EBITDA of 1.92 Million SEK for 2024 Q1, up 108.79% from previous quarter.
SenzaGen AB reported a quarterly EBITDA of -3.27 Million SEK for 2023 Q4, down -79.56% from previous quarter.

Annual EBITDA Chart of SenzaGen AB (2023 - 2014)

Historical Annual EBITDA of SenzaGen AB (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	-13.53 Million SEK	38.02%
2022	-15.35 Million SEK	60.95%
2021	-27.07 Million SEK	-16.74%
2020	-25.38 Million SEK	33.23%
2019	-34.75 Million SEK	-80.18%
2018	-19.28 Million SEK	-20.55%
2017	-15.99 Million SEK	-44.64%
2016	-11.05 Million SEK	-140.6%
2015	-4.59 Million SEK	-1101.31%
2014	361.35 Thousand SEK	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-2.94 Million SEK	-1830.9%
2024 Q1	1.92 Million SEK	108.79%
2023 Q4	-3.27 Million SEK	-79.56%
2023 Q2	-3.27 Million SEK	-29690.91%
2023 FY	- SEK	38.02%
2023 Q1	-11 Thousand SEK	99.7%
2023 Q3	-1.82 Million SEK	44.31%
2022 Q2	-3.36 Million SEK	0.0%
2022 Q4	-3.66 Million SEK	0.0%
2022 FY	- SEK	60.95%
2022 Q1	-3.36 Million SEK	60.35%
2022 Q3	-3.66 Million SEK	-8.9%
2021 Q2	-6.04 Million SEK	0.0%
2021 FY	- SEK	-16.74%
2021 Q4	-8.49 Million SEK	0.0%
2021 Q3	-8.49 Million SEK	-40.5%
2021 Q1	-6.04 Million SEK	8.91%
2020 Q1	-6.06 Million SEK	71.41%
2020 FY	- SEK	33.23%
2020 Q4	-6.63 Million SEK	0.73%
2020 Q3	-6.68 Million SEK	-10.22%
2020 Q2	-6.06 Million SEK	0.0%
2019 Q3	-11.17 Million SEK	36.63%
2019 Q2	-17.63 Million SEK	-152.16%
2019 Q1	-6.99 Million SEK	-20.96%
2019 FY	- SEK	-80.18%
2019 Q4	-21.22 Million SEK	-89.92%
2018 FY	- SEK	-20.55%
2018 Q1	-3.92 Million SEK	3.64%
2018 Q2	-3.92 Million SEK	0.0%
2018 Q3	-5.78 Million SEK	-47.48%
2018 Q4	-5.78 Million SEK	0.0%
2017 Q2	-3.93 Million SEK	0.0%
2017 FY	- SEK	-44.64%
2017 Q3	-4.06 Million SEK	-3.41%
2017 Q1	-3.93 Million SEK	-31.46%
2017 Q4	-4.06 Million SEK	0.0%
2016 FY	- SEK	-140.6%
2016 Q3	-2.99 Million SEK	-18.0%
2016 Q2	-2.53 Million SEK	0.0%
2016 Q1	-2.53 Million SEK	0.0%
2016 Q4	-2.99 Million SEK	0.0%
2015 FY	- SEK	-1101.31%
2014 FY	- SEK	0.0%

Peer EBITDA Comparison of SenzaGen AB

Name	EBITDA	EBITDA Difference
AroCell AB (publ)	-13.75 Million SEK	1.621%
Devyser Diagnostics AB (publ)	-43.8 Million SEK	69.096%
Immunovia AB (publ)	-166.55 Million SEK	91.873%
Prostatype Genomics AB (publ)	-38.02 Million SEK	64.398%
Spermosens AB	-10.7 Million SEK	-26.457%